Treats active duodenal ulcer. ANDA 77255, held by Teva Pharmaceuticals. Lansoprazole.
As of Nov 21, 2026, ANDA 77255 (Lansoprazole), held by Teva Pharmaceuticals, was first approved by FDA on Nov 10, 2009, with 13 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2009 | Original application | Approved |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Oct 15, 2021 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 1, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jul 1, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 1, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 1, 2019 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 2, 2015 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 30, 2013 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 30, 2013 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 18, 2012 | Supplement 2Labeling | Approved | None posted |
| Apr 18, 2012 | Supplement 4Labeling | Approved | None posted |
| Apr 18, 2012 | Supplement 6Labeling | Approved | None posted |
| Apr 18, 2012 | Supplement 8Labeling | Approved | None posted |
| Apr 16, 2012 | Supplement 10Labeling | Approved | None posted |
| Nov 10, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters